Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$255.36 -0.60 (-0.23%)
At close: Sep 28, 2026 · 4:00 PM EDT

Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026)

Updated

Alnylam Pharmaceuticals (ALNY) reported Change in Accured Expenses of $61.62 million for Q2 2026, down 61.1% from $158.23 million a year earlier.

Analysis

Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Alnylam Pharmaceuticals' Change in Accured Expenses came in at -$39.84 million; for FY2025, it came in at $75.07 million, down 17.6% from FY2024.

  • Change in Accured Expenses has a five-year compound annual growth rate of -12.2% (FY2020 to FY2025).
  • By year, Change in Accured Expenses came in at $91.09 million in FY2024 (+12.7%), $80.84 million in FY2023 (-57.8%), $191.77 million in FY2022 (+117.3%) and $88.24 million in FY2021 (-38.6%).
  • Five-year quarterly Change in Accured Expenses spans a low of -$176.03 million in Q1 2026 and a high of $249.43 million in Q3 2025.
  • Year over year, Change in Accured Expenses gained in two of the last four quarters, with growth averaging 55.0%.
  • The high point for year-over-year Change in Accured Expenses in five years was Q3 2025 (growth of 198.4%); the low point was Q2 2026 (a decline of 61.1%).
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$176.03 million (Q1 2026), -$174.85 million (Q4 2025) and $249.43 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn 2.96 Bn
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn 1.20 Bn
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn -
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn -251.00 Mn
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn -
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn 901.00 Mn
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn 338.00 Mn
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn 222.50 Mn
10 Alnylam Pharmaceuticals 34.23 Bn 22.28 Bn 992.69 Mn 61.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 61.62 Mn
Mar 31, 2026 -176.03 Mn
Dec 31, 2025 -174.85 Mn
Sep 30, 2025 249.43 Mn
Jun 30, 2025 158.23 Mn
Mar 31, 2025 -157.74 Mn
Dec 31, 2024 -62.11 Mn
Sep 30, 2024 83.60 Mn
Jun 30, 2024 74.47 Mn
Mar 31, 2024 -4.87 Mn
Dec 31, 2023 -38.67 Mn
Sep 30, 2023 118.74 Mn
Jun 30, 2023 82.74 Mn
Mar 31, 2023 -81.98 Mn
Dec 31, 2022 102.62 Mn
Sep 30, 2022 69.75 Mn
Jun 30, 2022 68.14 Mn
Mar 31, 2022 -48.74 Mn
Dec 31, 2021 39.50 Mn
Sep 30, 2021 46.36 Mn
API Access

Alnylam Pharmaceuticals Change in Accured Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=ALNY&period=max&api_key=YOUR_API_KEY